Cargando…

Health Canada's use of its priority review process for new drugs: a cohort study

OBJECTIVES: Priority reviews of new drug applications are resource intensive and drugs approved through this process have a greater likelihood of acquiring a serious safety warning compared to drugs approved through the standard process. Therefore, when Health Canada uses priority reviews, it is imp...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lexchin, Joel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431066/ https://www.ncbi.nlm.nih.gov/pubmed/25967989 http://dx.doi.org/10.1136/bmjopen-2014-006816

Ejemplares similares

Health Canada's Proposal to Accelerate New Drug Reviews
por: Lexchin, Joel
Publicado: (2020)

Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA
por: Hiayev, Stephany, et al.
Publicado: (2023)

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2016)

Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting
por: Pike, Eva, et al.
Publicado: (2017)

Potentially inappropriate prescribing and its association with health outcomes in middle-aged people: a prospective cohort study in Ireland
por: Moriarty, Frank, et al.
Publicado: (2017)

Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study
por: Lexchin, Joel
Publicado: (2018)

Determination of risk factors for drug-related problems: a multidisciplinary triangulation process
por: Kaufmann, Carole P, et al.
Publicado: (2015)

How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001–2012
por: Ward, Derek J, et al.
Publicado: (2014)

Nurse-led medicines’ monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines
por: Jordan, Sue, et al.
Publicado: (2018)

Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2020)

How are drug regimen changes during hospitalisation handled after discharge: a cohort study
por: Viktil, Kirsten K, et al.
Publicado: (2012)

How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009
por: Lexchin, Joel
Publicado: (2014)

Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK
por: Bjerre, Lise M, et al.
Publicado: (2018)

Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)
por: Kravchenko, Olga V, et al.
Publicado: (2022)

Assessment of drug use pattern using WHO core drug use indicators in selected general hospitals: a cross-sectional study in Tigray region, Ethiopia
por: Tassew, Segen Gebremeskel, et al.
Publicado: (2021)

Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study
por: Sadowski, Alexander, et al.
Publicado: (2013)

Trends of prescribing antimicrobial drugs for urinary tract infections in primary care in the Netherlands: a population-based cohort study
por: Mulder, Marlies, et al.
Publicado: (2019)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study
por: Lexchin, Joel
Publicado: (2022)

Prediction of therapeutic value of new drugs approved by health Canada from 2011−2020: A cross-sectional study
por: Lexchin, Joel
Publicado: (2023)

Incidence, risk factors and risk prediction of hospital-acquired suspected adverse drug reactions: a prospective cohort of Ugandan inpatients
por: Kiguba, Ronald, et al.
Publicado: (2017)

Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review
por: Lunghi, Carlotta, et al.
Publicado: (2022)

Health Canada: optimizing transparency and its impact for patients
por: Abi-Jaoude, Elia, et al.
Publicado: (2021)

New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis
por: Lexchin, Joel
Publicado: (2023)

Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink
por: Walker, Venexia M, et al.
Publicado: (2016)

Clarity and applicability of adverse drug reaction-related monitoring instructions in clinical practice guidelines for children and adolescents treated with antipsychotic drugs: a review of six clinical practice guidelines
por: Minjon, Lenneke, et al.
Publicado: (2022)

Behaviour change interventions to promote prescribing of generic drugs: a rapid evidence synthesis and systematic review
por: Moe-Byrne, Thirimon, et al.
Publicado: (2014)

Evaluation of exposure to effervescent drugs in a large health check-up population in France: a cross-sectional study
por: Perrin, Germain, et al.
Publicado: (2018)

A prospective study of adverse drug reactions to antiepileptic drugs in children
por: Anderson, Mark, et al.
Publicado: (2015)

Time to potential for listing of new drugs on public and private formularies in Canada: a cross-sectional study
por: Lexchin, Joel
Publicado: (2022)

Predicting the risk of drug–drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study
por: Wolff, Jan, et al.
Publicado: (2021)

Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study
por: Lexchin, Joel
Publicado: (2014)

Health Canada’s use of expedited review pathways and therapeutic innovation, 1995–2016: cross-sectional analysis
por: Lexchin, Joel
Publicado: (2018)

Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study
por: Rogers, Amy, et al.
Publicado: (2022)

Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden
por: Loikas, Desirée, et al.
Publicado: (2013)

Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents
por: Cornelius, Victoria R, et al.
Publicado: (2016)

Use and safety of azithromycin in neonates: a systematic review
por: Smith, Coral, et al.
Publicado: (2015)

Retrospective cohort study to evaluate medication use in patients hospitalised with COVID-19 in Scotland: protocol for a national observational study
por: Mueller, Tanja, et al.
Publicado: (2021)

Time to Marketing of Generic Drugs After Patent Expiration in Canada
por: Lexchin, Joel
Publicado: (2021)

Surveillance of adverse drug reactions at an adverse drug reaction monitoring centre in Central India: a 7-year surveillance study
por: Sharma, Megha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aarqj673fsjqm0ub6tqkfp39dt